Study guide
6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
Key Takeaways Explain This Topic AI
Impella microaxial flow pumps continuously unload the left ventricle by drawing blood directly from the LV lumen and ejecting it into the ascending aorta, significantly reducing LV end-diastolic pressure, wall tension, and myocardial oxygen demand while augmenting systemic organ perfusion.
Impella management requires strict adherence to purge fluid protocols (typically hypertonic dextrose with heparin or bicarbonate) to prevent blood ingress into the motor housing, alongside diligent monitoring for suction events, catheter displacement, and intravascular hemolysis (plasma free hemoglobin >40 mg/dL and elevated LDH).
Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) provides dual hemodynamic and respiratory support but increases LV afterload; failure of native LV ejection can lead to severe LV distension, pulmonary edema, and intracardiac thrombus, necessitating LV decompression strategies such as ECPELLA (Impella + ECMO).
Differential hypoxemia (Harlequin or North-South syndrome) during peripheral VA-ECMO occurs when recovering native LV ejects poorly oxygenated blood from damaged lungs to the coronary and carotid arteries while oxygenated ECMO blood perfuses the lower extremities; right radial arterial line SpO2/PaO2 monitoring is mandatory.
Durable continuous-flow LVADs (e.g., HeartMate 3) produce non-pulsatile blood flow, requiring MAP measurement via Doppler sphygmomanometer (target 70-80 mmHg), meticulous driveline site care, and vigilant screening for classic complications including RV failure, pump thrombosis, and AVM-driven gastrointestinal bleeding.
Last updated: August 2026
Impella Percutaneous Microaxial Flow Pumps
The Impella family of percutaneous microaxial continuous-flow blood pumps provides direct mechanical unloading of the ventricles. Inserted retrogradely across the aortic valve (for left-sided support), the device draws oxygenated blood directly from the left ventricular lumen via an inlet area near the catheter tip and expels it continuously into the ascending aorta through an outlet area above the aortic valve. Impella Anatomical Flow Circuit:
- [Left Ventricle Cavity (Inlet)] ===(Microaxial Impeller Motor)===> [Ascending Aorta (Outlet)]
- Result: Direct LV Volume Unloading + Parallel Systemic Perfusion Surge
- Physiological Effects of Direct LV Unloading
Unlike counterpulsation, which relies on native LV stroke volume, Impella active pumping operates in parallel with the native heart:
Decreases LV End-Diastolic Pressure (LVEDP) & LV End-Diastolic Volume (LVEDV): Actively aspirating blood from the LV reduces intramyocardial wall tension.
Dramatically Lowers Myocardial Oxygen Consumption (MVO₂): By performing the mechanical work of volume displacement, myocardial workload and oxygen demand collapse.
Increases Mean Arterial Pressure (MAP) and Cardiac Index (CI): Expelling 2.5 to 5.5 L/min of blood directly into the ascending aorta augments systemic and coronary perfusion regardless of native LV contractility.
Impella Device Portfolio
Device Model Access Route Sheath / Catheter Size Maximum Flow Rate Primary Clinical Application
Impella 2.5 Femoral Artery 12 Fr pump motor via a 13 Fr introducer (9 Fr stem) Up to 2.5 L/min High-risk PCI, mild cardiogenic shock
Impella CP Femoral Artery 14 Fr Sheath (9 Fr stem) Up to 3.5–4.0 L/min Acute cardiogenic shock post-AMI
Impella 5.5 Transaxillary / Subclavian Artery 9 Fr stem / 19 Fr pump motor Up to 5.5 L/min Severe cardiogenic shock, bridge-to-transplant/LVAD
Impella RP Femoral Vein (Right-sided) 11 Fr Catheter (22 Fr motor) Up to 4.0 L/min Acute RV failure (inlet in IVC/RA, outlet in PA)
- Purge System, Alarm Management & Hemolysis Protocols
- Purge Fluid Management
The internal motor of the Impella pump relies on a continuous hyperbaric fluid purge system to prevent blood from entering the motor housing, which would cause rotor drag and pump failure.
Purge Solution: Hypertonic Dextrose (D5W, D10W, or D20W) combined with Heparin (25 or 50 units/mL) .
HIT Protocol: In patients with confirmed or suspected Heparin-Induced Thrombocytopenia (HIT), heparin is omitted and Sodium Bicarbonate (25 mEq/L in D5W) is substituted as the purge additive.
Purge Pressure Range: Maintains a positive pressure gradient between 300 and 1100 mmHg at flow rates of 2 to 30 mL/hr.
Purge Alarm Troubleshooting
High Purge Pressure / Low Purge Flow: Caused by purge line kink, dextrose crystallization within the motor, or purge fluid obstruction. Nursing Action: Check tubing for kinks, flush purge line, replace purge cassette, or lower dextrose concentration if crystallization occurs.
Low Purge Pressure / High Purge Flow: Caused by a leak in the purge tubing, loose connections, or purge disc structural damage. Nursing Action: Inspect all connections, tighten Luer-locks, replace purge cassette.
Suction Events & Catheter Displacement
Suction occurs when the pump inlet becomes obstructed by the LV wall, papillary muscles, or when the LV becomes severely volume-depleted.
Recognition: Rapid drop in flow rate, high motor current fluctuations, and console "Suction" alarms.
Hemodynamic Impact: Intravascular hemolysis, myocardial wall damage, and sudden drop in cardiac output.
Nursing Actions: Check fluid balance; if hypovolemic, administer a fluid bolus; temporarily decrease performance level (P-level); verify catheter position via transthoracic (TTE) or transesophageal (TEE) echocardiography.
Optimal Anatomical Position: The inlet area must sit 3.5 to 4.5 cm below the aortic valve annulus , angled toward the LV apex and away from the mitral valve apparatus.
Intravascular Hemolysis Monitoring
High shear stress generated by the rapidly spinning impeller motor (model-specific: Impella 2.5 up to 51,000 rpm, CP up to 46,000 rpm, 5.0/5.5 up to 33,000 rpm) can lyse red blood cells if the catheter is positioned suboptimally.
Diagnostic Markers: Plasma free hemoglobin ( pfHb > 40 mg/dL is diagnostic of clinical hemolysis), serum Lactate Dehydrogenase (LDH) elevation, low serum haptoglobin (< 10 mg/dL), and dark reddish-brown ("tea-colored") urine (hemoglobinuria).
Management: Obtain STAT echocardiogram to assess for catheter displacement or inlet obstruction, re-position pump under imaging, and lower P-level.
Loading diagram... Hemodynamic Comparison & ECPELLA LV Decompression Synergy
Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)
Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) provides temporary total cardiopulmonary support for patients in refractory cardiogenic shock or cardiac arrest (E-CPR). Deoxygenated venous blood is drained from the right atrium or vena cava, pumped through a membrane oxygenator/heat exchanger, and returned under high arterial pressure into the systemic arterial system.
VA-ECMO Circuit Configurations
Peripheral VA-ECMO: Venous drainage cannula in femoral vein (tip in RA/IVC); arterial return cannula in femoral artery. Blood flows retrogradely up the descending aorta toward the aortic arch.
Central VA-ECMO: Venous cannula in RA; arterial cannula directly in ascending aorta (post-cardiotomy).
The LV Distension Hazard & Decompression Strategies
Because peripheral VA-ECMO pumps blood retrogradely into the aorta, it markedly increases left ventricular afterload . If the native LV is severely stunned and incapable of generating sufficient pressure to open the aortic valve:
The LV becomes acutely distended with blood from bronchial veins and residual pulmonary venous return.
LVEDP surges to extreme levels, causing backward transmission into pulmonary capillaries, fulminant cardiogenic pulmonary edema, intra-ventricular stagnation, and high risk of intracardiac thrombus formation. VA-ECMO Retrograde Flow ---> Increased Aortic Root Afterload ---> LV Stunned/Aortic Valve Closed
- └──> Acute LV Distension ---> Surging LVEDP ---> Fulminant Pulmonary Edema & Intra-LV Thrombus
- LV Decompression (Venting) Strategies
To prevent or treat LV distension on VA-ECMO, active unloading strategies must be employed:
ECPELLA Strategy: Concomitant insertion of an Impella microaxial pump alongside peripheral VA-ECMO. Impella actively vents the LV, maintaining low LVEDP while ECMO provides oxygenation and high systemic flow.
Percutaneous Balloon Atrial Septostomy: Creating an interatrial communication to decompress the left atrium into the right atrium.
Intra-Aortic Balloon Pump (IABP): Co-therapy to lower LV afterload during diastolic deflation.
Surgical LV Apical Vent: Direct venting catheter placed in the LV apex.
Harlequin Syndrome (Differential Hypoxemia)
In peripheral femoral VA-ECMO, Harlequin Syndrome (also termed North-South Syndrome) occurs when native left ventricular contractility begins to recover, but severe lung injury (e.g., ARDS or pulmonary edema) persists.
Pathophysiology: The recovering LV ejects poorly oxygenated blood (from diseased lungs) into the ascending aorta, forming a mixing cloud where retrograde oxygenated blood from the ECMO circuit meets antegrade deoxygenated blood from the LV. If the mixing cloud shifts distally, the coronary arteries and carotid vessels receive hypoxemic blood , while the lower extremities receive well-oxygenated ECMO blood.
Monitoring Mandatory: An arterial line MUST be placed in the Right Radial Artery to continuously monitor arterial blood gases (PaO₂) and oxygen saturation (SpO₂) supplying the heart and brain. Target: Right radial SpO₂ > 92% and PaO₂ > 60–70 mmHg.
Management: Improve lung ventilation, add a venous re-infusion line into the right internal jugular vein (converting circuit to Veno-Arterial-Venous [VAV-ECMO]), or convert to central ECMO.
Durable Continuous-Flow LVADs (HeartMate 3)
Durable continuous-flow Left Ventricular Assist Devices (LVADs), such as the HeartMate 3 , are surgically implanted for end-stage heart failure as a Bridge-to-Transplant (BTT) or Destination Therapy (DT).
Continuous-Flow Mechanics & Non-Pulsatile Hemodynamics
Full MagLev Technology: The HeartMate 3 utilizes a magnetically levitated rotor operating without mechanical bearings, producing continuous centrifugal blood flow with an artificial pulse pattern (pulsatility gap) designed to reduce blood stasis.
Non-Pulsatile Hemodynamics: Patients typically lack a palpable peripheral pulse or standard audible blood pressure.
Blood Pressure Measurement: Mean Arterial Pressure (MAP) MUST be measured using a Doppler sphygmomanometer combined with a manual blood pressure cuff. The pressure at which the first continuous Doppler arterial flow signal is re-established during cuff deflation represents the MAP. Target MAP: 70 to 80 mmHg (MAP > 85 mmHg dramatically increases pump afterload, decreasing flow and escalating stroke risk).
Driveline Care & Infection Prevention
The percutaneous driveline exits the abdominal wall to connect the internal pump to the external system controller and power sources (batteries/AC power).
Driveline Exit Site Infections (DESI) represent the leading cause of morbidity. Sterile technique is mandatory during all dressing changes, utilizing chlorhexidine antisepsis, sterile gloves, and dedicated driveline anchor/stabilization devices to eliminate mechanical traction trauma.
Key Clinical Complications of Continuous-Flow LVADs
Complication Pathophysiological Mechanism Clinical Indicators & Diagnostics Emergency Nursing Interventions
Right Ventricular Failure (RVF) Increased venous return from LVAD overwhelms a non-compliant RV; leftward septal shift impairs RV geometry. High CVP (>18 mmHg), low LVAD flow rates, peripheral edema, ascites, elevated bilirubin. Administer inotropes (dobutamine, milrinone), pulmonary vasodilators (inhaled epoprostenol), optimize RV preload, prepare for RVAD.
Pump Thrombosis Thrombus deposition in pump housing or cannulae due to inadequate anticoagulation or shear stress. Sudden spike in pump power (wattage) with an erroneously HIGH displayed flow (displayed flow is estimated from power, so thrombus inflates it), hematuria, elevated plasma free Hb and LDH. A genuine flow drop with falling power instead suggests outflow-graft obstruction or a twist. STAT anticoagulation escalation, thrombolytic therapy, or emergent surgical pump exchange.
Gastrointestinal Bleeding (AVMs) Continuous high shear stress cleaves high-molecular-weight vWF (acquired vWF syndrome); mucosal hypoperfusion promotes arteriovenous malformations. Melena, hematochezia, unexplained hemoglobin drop, low flow alarms. Blood transfusions, IV Octreotide, lower INR target (2.0–2.5), GI endoscopy with cauterization.
Suckdown / Suction Event Impeller pulls LV wall into inflow cannula due to severe hypovolemia, RV failure, or cardiac tamponade. Sudden drop in flow rate, low flow alarms, ventricular arrhythmias, chest pain. Administer IV fluid bolus, decrease LVAD pump speed (RPM), obtain STAT echocardiogram.